GSK Cervarix Clears Landmark FDA Vaccine Committee with Okay for Novel Adjuvant
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's two-year delay to do more safety work on the vaccine and specifically on the AS04 adjuvant gets the sponsor past one major milestone with a strong vote on safety for use in girls and young women.
You may also be interested in...
Vaccine Adjuvant Heightens Panel’s Worries About Rare Adverse Events With Heplisav
FDA’s Vaccines and Related Biological Products Advisory Committee recommended 8 to 5 with one abstention that Dynavax acquire more safety data pre-licensure for its hepatitis B vaccine.
FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Narrows Population
The firm is hoping to gain licensure for chronic kidney disease patients first, and eventually to expand the indication to the broader hepatitis B vaccination population.
FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Narrows Population
The firm is hoping to gain licensure for chronic kidney disease patients first, and eventually to expand the indication to the broader hepatitis B vaccination population.